Evidence map›Paper›PMID 36423008›Full record

ReviewVaccines2022

Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State.

Ayazhan Akhatova, Azliyati Azizan, Kuralay Atageldiyeva, Aiymkul Ashimkhanova, Aizada Marat, Yerbolat Iztleuov, Assem Suleimenova, Saikal Shamkeeva, Gulzhanat Aimagambetova

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Ayazhan AkhatovaSchool of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.
Azliyati AzizanDepartment of Basic Sciences, College of Osteopathic Medicine, Touro University, Henderson, NV 89014, USA.
Kuralay AtageldiyevaDepartment of Medicine, School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0002-7048-1511
Aiymkul AshimkhanovaDepartment of Medicine, School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.
Aizada MaratDepartment of Obstetrics and Gynecology #1, NJSC "Astana Medical University", Astana 010000, Kazakhstan.
Yerbolat IztleuovMedical Center, Marat Ospanov West-Kazakhstan Medical University, Aktobe 030000, Kazakhstan.
Assem SuleimenovaKazakh Institute of Oncology and Radiology, Almaty 050000, Kazakhstan.
Saikal ShamkeevaInstitute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Leipzig University Hospital, 04103 Leipzig, Germany.ORCID 0000-0001-9166-1872
Gulzhanat AimagambetovaDepartment of Biomedical Sciences, School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0002-2868-4497
Nazarbayev University · KZAstana Medical University · KZKazakh Institute of Oncology and Radiology · KZKazakhstan Medical University · KZUniversity Hospital Leipzig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunization is the most successful method in preventing and controlling infectious diseases, which has helped saving millions of lives worldwide. The discovery of the human papillomavirus (HPV) infection being associated with a variety of benign conditions and cancers has driven the development of prophylactic HPV vaccines. Currently, four HPV vaccines are available on the pharmaceutical market: Cervarix, Gardasil, Gardasil-9, and the recently developed Cecolin. Multiple studies have proven the HPV vaccines' safety and efficacy in preventing HPV-related diseases. Since 2006, when the first HPV vaccine was approved, more than 100 World Health Organization member countries reported the implementation of HPV immunization. However, HPV vaccination dread, concerns about its safety, and associated adverse outcomes have a significant impact on the HPV vaccine implementation campaigns all over the world. Many developed countries have successfully implemented HPV immunization and achieved tremendous progress in preventing HPV-related conditions. However, there are still many countries worldwide which have not created, or have not yet implemented, HPV vaccination campaigns, or have failed due to deficient realization plans associated with establishing successful HPV vaccination programs. Lack of proper HPV information campaigns, negative media reflection, and numerous myths and fake information have led to HPV vaccine rejection in many states. Thus, context-specific health educational interventions on HPV vaccination safety, effectiveness, and benefits are important to increase the vaccines' acceptance for efficacious prevention of HPV-associated conditions.

Indexed as

CecolinCervarixcervical cancer preventionGardasilGardasil-9HPVHPV vaccinationHPV vaccination acceptanceprophylactic HPV vaccine

Identifiers

PMID36423008
PMCPMC9696339
OpenAlexW4309006731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.